China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced the first subject dosing in a clinical study for its B-cell lymphoma-2 (BCL2) inhibitor ICP-248. The study, approved in China in September last year, marks a significant step in the development of this novel therapy.
Drug Profile and Indications
ICP-248 is a novel, orally bioavailable BCL2 selective inhibitor under development to treat non-Hodgkin’s lymphoma (NHL), acute lymphoblastic leukemia (ALL), and other malignant hematological tumors. The drug can be used as a monotherapy or in combination with BTK inhibitors and other drugs. BCL2 is an important regulatory protein of the apoptosis pathway, and its abnormal expression is related to the development of various hematologic malignancies.
Mechanism of Action
ICP-248 exerts its anti-tumor effect by selectively inhibiting BCL2, thereby restoring the mechanism of programmed cell death. This targeted approach aims to address the underlying causes of tumor growth and progression in hematological malignancies.
Significance of the Clinical Study
The initiation of the clinical study for ICP-248 highlights InnoCare Pharma’s commitment to advancing innovative treatments for patients with lymphoma and leukemia. By targeting BCL2, ICP-248 has the potential to offer a new therapeutic option for these challenging diseases, potentially improving patient outcomes and quality of life.-Fineline Info & Tech
